Zantac deadline ruling a reprieve for drug giants
ShareS in (GSK) and its spin-out got a boost after a rare piece of good news concerning a legal wrangle over the pharmaceutical giant’s former heartburn drug Zantac.
The once-popular drug in the US and UK, which was developed by GSK, was pulled from shelves in 2019 amid fears it contained a cancer-causing chemical.
The incident has led to more than 2,000 cases being filed in the US, raising fears that pharma giants which had sold it could be held liable to pay hefty damages.
haleon, which was split off from GSK last month, could also be on the hook after the drugmaker served notice that it could request payments to help settle any damages claims.
But GSK rose 0.3pc, or 4.4p, to 1394.8p after analysts at investment bank Citi highlighted that a recent ruling by a US judge overseeing the lawsuits could mean 70,000 plaintiffs could be forced to abandon their claims due to the statute of limitations, which sets a time limit in which someone is allowed to bring legal action.
The assessment also lifted haleon 1pc, or 2.7p to 266.3p. Citi said if its predictions were accurate the number of plaintiffs in lawsuits would be ‘materially lower’ than originally feared.
If that happens, shares in GSK and French rival Sanofi, which also sold Zantac, could surge by over 40pc. Citi’s estimates will come as a relief to both GSK and haleon – shares of which have been battered over the last few weeks.
The FTSE 100 fell 0.7pc, or 52.43 points, to 7427.31 while the FTSE 250 dipped 0.5pc, or 88.15 points, to 19,169.72. Markets managed to maintain a cautious optimism despite the surge in Ofgem’s energy price cap, which will see millions of UK households suffer an 80pc rise in bills from October.
Things were less optimistic on the continent with German consumer confidence at a record low as fears of a recession mount.
‘Germany is concerned about rising energy costs in particular, and is particularly reliant on external producers, making the situation more fraught. People are saving at the highest levels in 11 years, showing that consumers are taking tangible precautions in case of the worst-case scenario,’ said hargreaves Lansdown analyst Sophie Lund-Yates.
One beneficiary of the looming price cap hike appeared to be British Gas owner Centrica, up 0.6pc, or 0.52p, to 81.96p.
Oil stocks came under focus as Brent crude hovers around $100 a barrel amid predictions global supply will continue to be constrained as potential output cuts by the OPeC+ cartel cancel out an expected rise in exports from Iran. Shell was up 0.6pc, or 13.5p, at 2334p but BP inched down 0.4pc, or 1.65p, to 457.8p.
holiday Inn owner Intercontinental Hotels dropped 4.4pc, or 216p, to 4750p after analysts at investment bank JP Morgan lowered the stock rating to ‘neutral’ from ‘overweight’ and cut its price target to 5900p from 6100p, saying they saw ‘limited upside’ for the shares now most hotels had reopened.
rival Whitbread, the owner of Premier Inn, was also trimmed by JP Morgan, which cut its target to 4100p from 4150p. Whitbread fell 1.8pc, or 47p, to 2507p.
Mid-cap fund manager JTC unveiled plans to snap up New York Private Trust Company, which offers services to rich people. JTC fell 0.3pc, or 2p, to 759p.
Meanwhile, computer game maker Tinybuild is to buy rival Konfa Games for up to £4.6m in a cash and share deal, and the intellectual property portfolio of Bossa Studios, maker of titles such as I am Fish, for £2.5m. Tinybuild rose 0.4pc, or 0.5p, to 115.5p.